| 摘要 |
A substituted quinoxaline 2,3- dione or a pharmaceutically acceptable salt thereof, has the formula I wherein: R is an optionally substituted mono-, bi-cyclic spiro ring non-aromatic attached to the quinoxaline ring through (-CH2)n and at the a- or b-position or R is a group of formula 2 having 4 to 7 atoms or a group of formula 3 having 8 to 12 atoms; n is 1 to 4; R1 is hydrogen, alkyl, aralkyl, carboxyalkyl, or phosphonoalkyl; R2 is hydrogen, hydroxy, or amino; R3 and R4 are each independently hydrogen, alkyl, alkenyl, cycloalkyl, halogen, haloalkyl, nitro, cyano, SO2CF3, CH2SO2R6, (CH2)mCO2R6, (CH2)mCONR7R8, (CH2)mSO2NR7R8, or NHCOR6; R5 is hydrogen, alkyl, alkenyl, cycloalkyl, halogen, haloalkyl, aryl, aralkyl, heteroaryl, nitro, cyano, SO2CF3, (CH2)mCO2R9, (CH2)mCONR9R10, SO2NR9R10, or NHCOR9 and R5 may be at the a-position and R-(CH2)- at the b-position on the ring; m is 0 to 4 and R6 to R11 are as defined in the specification. A pharmaceutical composition thereof is useful for treating stroke, Parkinson's disease, Huntington's disease, or cerebral hypoxia/ischemia.
|
